Nobilis Health Corp.
NRTSF · OTC
6/30/2018 | 3/31/2018 | 12/31/2017 | 9/30/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.22 | 0.04 | 0.02 | -0.58 |
| FCF Yield | -0.68% | 1.57% | -2.07% | 7.13% |
| EV / EBITDA | 23.23 | 65.37 | 10.64 | 41.84 |
| Quality | ||||
| ROIC | 0.92% | -0.64% | 2.02% | -0.01% |
| Gross Margin | 61.43% | 59.44% | 64.86% | 59.60% |
| Cash Conversion Ratio | 0.04 | -0.85 | -0.16 | 9,583.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.70% | 6.84% | 9.47% | 20.92% |
| Free Cash Flow Growth | -131.32% | 193.06% | -126.14% | 302.76% |
| Safety | ||||
| Net Debt / EBITDA | 13.18 | 31.11 | 5.54 | 13.32 |
| Interest Coverage | 1.25 | -0.95 | 8.35 | 0.93 |
| Efficiency | ||||
| Inventory Turnover | 8.25 | 8.31 | 9.09 | 7.49 |
| Cash Conversion Cycle | 117.61 | 132.73 | 88.02 | 102.44 |